Travis Cordie, M.S. joined the team in 2016, bringing with his knowledge of bio manufacturing, genetic engineering, pluripotent stem cells and tissue engineering. Graduating from UW-Madison with a M.S. in Biomedical Engineering, studied reprogramming human pluripotent stem cells and tissue engineering. Post graduate school Travis worked at a Biomanufacturing facility gaining valuable cGMP experience and developing cellular therapies for phase 1 and 2 clinical trials.
Dr. Leah Hogdal, Ph.D. is a senior scientist at B-MoGen Biotechnologies and has extensive experience in mitochondrial, genetic, and cellular biology. She graduated summa cum laude from Gustavus Adolphus College with a degree in Honors Biology, received her PhD in Biological Chemistry and Molecular Pharmacology from Harvard University, and was a post-doctoral fellow at Vanderbilt University. Her doctoral and post-doctoral research focused on developing methods to predict mitochondrial apoptotic responses to cancer therapeutics in primary human cells.
Dr. Alicia Wallis, Ph.D. has extensive experience in the mechanisms required for controlling T cell activation and function to combat infection and disease. Her expertise includes quantitative analysis of signaling events, T cell functional output, and phenotypic analysis. Additionally, Dr. Wallis has experience in genetic modification of T cells using CRISPR/Cas9 technology. Dr. Wallis graduated from the University of Iowa with a Ph.D. in immunology where she spent 5 years studying the 3 signals required for T cell activation.
Dr. Sandeep Kumar, is an expert in protein engineering. His expertise includes site directed mutagenesis, Golden Gate and Gibson assembly. He has worked on various aspects of DNA replication initiation, replication checkpoint and HR. During his post-doctoral studies at Baylor College of Medicine he developed a FRET based screen to identify DNA2 inhibitors. Dr. Kumar received his PhD in Biochemistry from CDFD/ University of Hyderabad, India.